Literature DB >> 19874548

Insulin2 gene (Ins2) transcription by NOD bone marrow-derived cells does not influence autoimmune diabetes development in NOD-Ins2 knockout mice.

A Martin-Pagola1, A Pileggi, E Zahr, F Vendrame, R Damaris Molano, I Snowhite, C Ricordi, G S Eisenbarth, M Nakayama, A Pugliese.   

Abstract

Insulin is a critical autoantigen for the development of autoimmune diabetes in non-obese diabetic (NOD) mice. About 80% of NOD females and 30-40% of NOD males develop diabetes. However, Insulin2 (Ins2) knockout NOD mice develop autoimmune diabetes with complete penetrance in both sexes, at an earlier age, and have stronger autoimmune responses to insulin. The severe diabetes phenotype observed in NOD-Ins2-/- mice suggests that lack of Ins2 expression in the thymus may compromise immunological tolerance to insulin. Insulin is a prototypical tissue specific antigen (TSA) for which tolerance is dependent on expression in thymus and peripheral lymphoid tissues. TSA are naturally expressed by medullary thymic epithelial cells (mTEC), stromal cells in peripheral lymphoid tissues and bone marrow (BM)-derived cells, mainly CD11c(+) dendritic cells. The natural expression of TSA by mTEC and stromal cells has been shown to contribute to self-tolerance. However, it is unclear whether this also applies to BM-derived cells naturally expressing TSA. To address this question, we created BM chimeras and investigated whether reintroducing Ins2 expression solely by NOD BM-derived cells delays diabetes development in NOD-Ins2-/- mice. On follow-up, NOD-Ins2-/- mice receiving Ins2-expressing NOD BM cells developed diabetes at similar rates of those receiving NOD-Ins2-/- BM cells. Diabetes developed in 64% of NOD recipients transplanted with NOD BM and in 47% of NOD mice transplanted with NOD-Ins2-/- BM (P = ns). Thus, NOD-Ins2-/- BM did not worsen diabetes in NOD recipients and Ins2 expression by NOD BM-derived cells did not delay diabetes development in NOD-Ins2-/- mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874548     DOI: 10.1111/j.1365-3083.2009.02316.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

Review 1.  Treg vaccination with a strong-agonistic insulin mimetope.

Authors:  Benno Weigmann; Carolin Daniel
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 2.  Autoimmune Responses to Exosomes and Candidate Antigens Contribute to Type 1 Diabetes in Non-Obese Diabetic Mice.

Authors:  Yang D Dai; Huiming Sheng; Peter Dias; M Jubayer Rahman; Roman Bashratyan; Danielle Regn; Kristi Marquardt
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

Review 3.  Self-antigen expression in the peripheral immune system: roles in self-tolerance and type 1 diabetes pathogenesis.

Authors:  Rebecca Fuhlbrigge; Linda Yip
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

4.  MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice.

Authors:  Li Zhang; Pilar Londono; Liping Yu; Stephen Grimes; Peter Blackburn; Peter Gottlieb; George S Eisenbarth
Journal:  Autoimmunity       Date:  2014-05-01       Impact factor: 2.815

Review 5.  Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis.

Authors:  Muhammed Yüksel; Debby Laukens; Femke Heindryckx; Hans Van Vlierberghe; Anja Geerts; F Susan Wong; Li Wen; Isabelle Colle
Journal:  Int J Exp Pathol       Date:  2014-08-12       Impact factor: 1.925

6.  Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes.

Authors:  Li Zhang; Frances Crawford; Liping Yu; Aaron Michels; Maki Nakayama; Howard W Davidson; John W Kappler; George S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 7.  Immunotherapy in autoimmune type 1 diabetes.

Authors:  Benno Weigmann; Randi K Franke; Carolin Daniel
Journal:  Rev Diabet Stud       Date:  2012-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.